Genomma Lab Internacional S.A.B. de C.V
Genomma Lab Internacional, S.A.B. de C.V., together with its subsidiaries, provides pharmaceutical and personal care products primarily in Latin America. It develops, sells, and markets a range of branded products in the categories of anti-acne products, self-diagnosis, antibacterial, cream to improve the texture of scarred skin, shampoos, dandruff shampoos, soaps, razors, products to prevent hai… Read more
Genomma Lab Internacional S.A.B. de C.V - Asset Resilience Ratio
Genomma Lab Internacional S.A.B. de C.V (GNMLF) has an Asset Resilience Ratio of 8.08% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2015–2024)
This chart shows how Genomma Lab Internacional S.A.B. de C.V's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Genomma Lab Internacional S.A.B. de C.V's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $89.25 Million | 8.08% |
| Total Liquid Assets | $89.25 Million | 8.08% |
Asset Resilience Insights
- Limited Liquidity: Genomma Lab Internacional S.A.B. de C.V maintains only 8.08% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Genomma Lab Internacional S.A.B. de C.V Industry Peers by Asset Resilience Ratio
Compare Genomma Lab Internacional S.A.B. de C.V's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF |
Drug Manufacturers - Specialty & Generic | -0.02% |
|
Kamada
NASDAQ:KMDA |
Drug Manufacturers - Specialty & Generic | 21.63% |
|
Dongwha Pharm.Co.Ltd
KO:000020 |
Drug Manufacturers - Specialty & Generic | 1.92% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.46% |
|
Yuhan Corp.
KO:000100 |
Drug Manufacturers - Specialty & Generic | 0.99% |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153 |
Drug Manufacturers - Specialty & Generic | 1.81% |
|
Kotra Industries Bhd
KLSE:0002 |
Drug Manufacturers - Specialty & Generic | 9.82% |
|
Yuyu Pharma Inc
KO:000227 |
Drug Manufacturers - Specialty & Generic | 1.74% |
Annual Asset Resilience Ratio for Genomma Lab Internacional S.A.B. de C.V (2015–2024)
The table below shows the annual Asset Resilience Ratio data for Genomma Lab Internacional S.A.B. de C.V.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 8.08% | $89.25 Million | $1.10 Billion | -6.98pp |
| 2023-12-31 | 15.06% | $183.23 Million | $1.22 Billion | -3.53pp |
| 2022-12-31 | 18.59% | $205.93 Million | $1.11 Billion | -- |
| 2018-12-31 | 0.00% | $0.00 | $917.92 Million | -- |
| 2017-12-31 | 0.00% | $0.00 | $811.92 Million | -- |
| 2016-12-31 | 0.00% | $0.00 | $762.50 Million | -- |
| 2015-12-31 | 0.00% | $0.00 | $1.02 Billion | -- |